CTKB

Image source: The Motley Fool. Wednesday, Aug. 5, 2026 at 4:30 p.m. ET Chief Executive Officer - Wenbin Jiang Chief Financial Officer - William McCombe Investor Relations - Mark Meehan Operator: Hello, and thank you for standing by. My name is Lacey, and I will be your conference operator today. At this time, I would like to welcome everyone to the Cytek Biosciences second quarter 2026 earnings conference call. [Operator Instructions] I would now like to turn the call over to Mark Meehan. Please go ahead. Mark Meehan: Thank you, operator. Joining me today from Cytek are Wenbin Jiang, CEO, and Bill McCombe, CFO. Earlier today, Cytek Biosciences released financial results for the second quarter ended June 30, 2026. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to [email protected]. A copy of the news release is also available on the Investor Relations section of Cytek's website at investors.cytekbio.com. Please note that we will be referencing a slide presentation during the call today that has been posted to the investor section of our corporate website. As a reminder, on slide 2, we will make statements during this call that are forward-looking statements within the meaning of the federal securities laws, including statements regarding Cytek's business plans, strategies, opportunities, and financial projections. These statements are based on the company's current expectations and inherently involve significant risks and uncertainties that could cause actual results or events to materially differ from those anticipated in these statements. Additional information regarding these risks and uncertainties appears in our slide presentation in the section entitled forward-looking statements, in the press release Cytek issued today, and in Cytek's filings with the SEC. This call will also include a discussion of certain financial measures that are not calculated in accordance with generally accepted accounting principles. Additional information regarding our use of non-GAAP financial measures, including reconciliations to the most directly comparable GAAP financial measures, may be found on our slide presentation and in today's press release. While the company believes these non-GAAP financial measures provide useful information for investors, the presentation of this information is not intended to be considered in isolation or as a substitute for the financial information presented in accordance with GAAP. Except as required by law, Cytek disclaims any duty to update any forward-looking statements, whether because of new information, future events, or changes in its expectations. This conference call contains time-sensitive information and is accurate only as of the live broadcast, August 5, 2026. Finally, I would like to remind you of the organizational update we mentioned during our last call. During the third quarter of 2026, Cytek will begin operating as 3 distinct customer-aligned business units: Solutions and Clinical, Research Technology, and Service. For further details about these business units, please see the slide included in the appendix of our presentation. With that, I'll turn the call over to Wenbin. Wenbin Jiang: Thanks, Mark. Welcome, everyone, and thank you for your interest in Cytek. On today's call, I will start with a discussion on our performance in the second quarter and highlight a couple of exciting new product launches before turning the call over to Bill for a detailed look at our financials and our updated full year outlook. Turning to slide 3, we built upon our good start to the year with continued positive momentum through the second quarter, delivering another period of solid revenue growth. Second quarter 2026 revenue was $48.1 million, an increase of 6% year-over-year. Our second quarter performance was driven by strong double-digit revenue growth in the U.S. and in China. Mid-teens growth from our FSP instruments and consistent double-digit growth in our service business. Turning to slide 4, geographically in the United States, second quarter revenue was $28.2 million, an increase of 18% year-over-year. This maintains the strong trend from Q1 and reflects impressive growth in instrument revenue in the academic and government sector and in our service business. In EMEA, second quarter revenue was $11.3 million, down approximately 8% year-over-year, reflecting a continuation of the budgetary pressures arising from regional geopolitical dynamics. Total APAC revenue, including China, was $7.9 million, flat year-over-year. China delivered strong double-digit growth against a modest year-on-year comp, which was offset by softness in other parts of the region. Turning to slide 5. We continued to expand our global footprint in the second quarter, adding 142 units and bringing Cytek's total installed base to 3,933 units. We continue to see good instrument unit growth in the second quarter, driven by our high-end FSP instrument portfolio, which grew 11% year-over-year, and was led by Aurora Evo analyzer and Aurora CS cell sorter. Turning to slides 6 and 7, I want to additionally highlight 2 exciting new product launches that further extend our technology leadership and set the foundation for our next phase of growth. First, we recently introduced the Cytek Borealis, the industry's first 60-color, 7-laser, full spectrum flow cytometer. The advancement to resolve 60 unique colors in a single sample run was enabled by Borealis' unique technology, where 7 lasers operate simultaneously in concert with purpose-built and proprietary UV and IR dye reagents. The capability to analyze 60 colors in a single run significantly expands the range of cellular biomarkers that scientists can evaluate while retaining the direct hierarchy comparison benefits of a single tube sample. On top of the technological benefits that improve analytical capability, the Borealis also delivers increased efficiency for our customers, including the ability to analyze nanoparticles, which expands the diversity of sample types, high flow rate that increases the speed of the analysis and the throughput of the system, and enhanced automation that eliminates the need for manual sample handling. The Borealis system has also been designed to allow for the integration of onboard high-parameter cellular imaging capabilities. By incorporating imaging alongside advanced 60-color, 7-laser spectrum detection, Borealis will provide a more complete cellular view from a single sample, representing another meaningful step forward in what our customers can learn from each experiment. Feedback from our early access customers has been very strong, and we look forward to sharing more on Borealis as we progress toward greater commercial availability. Second, we introduced the new Aurora Evo instrument configuration with expanded automation capabilities. These enhancements enable the integration of full spectrum flow cytometry into highly automated laboratory environments by adding automated and the remote operation of key instrument functions, as well as an API for interfacing with automation plate handling systems, eliminating the need for a human operator. These capabilities are particularly relevant for biopharma organizations and CROs, where efficiency, reproducibility, and system integration are critical to large-scale programs. Taken together, these newly launched products underscore our continued commitment to extending our technology leadership while enabling cutting-edge research and driving lab productivity for our customers. Turning to applications and service, our recurring revenue base continued to strengthen in the second quarter. Combined reagent and service revenue was $18.5 million in Q2 2026, up 8% year-over-year, representing 35% of Cytek's last 12 months revenue, up from 32% for the 12 months to June 30, 2025. Our service revenue was $15.6 million in the second quarter, growing 10% year-over-year, driven by continued growth in our installed base and the high utilization of our instruments by customers worldwide. We expect recurring revenue to represent an increasing percentage of our total revenue over time, supported by high utilization and the continued expansion of our installed base. Moving to bioinformatics, the Cytek Cloud continues to play a critical role for researchers working to create and optimize experimental workflows and is also driving adoption and utilization of our cell analysis solutions. As of June 30, 2026, Cytek Cloud has surpassed 28,000 users, up 15% since the start of the year. Growth in Cytek Cloud users reinforces the strength of our integrated ecosystem and drives deeper customer engagement. We believe this increasing level of engagement is an important factor in driving growth in our reagent and service businesses. And with that, I will now turn the call over to Bill for additional details on our Q2 financials and our updated guidance. William McCombe: Thanks, Wenbin. Turning to slide 8, second quarter revenue was $48.1 million, an increase of 6% compared to $45.6 million in Q2 2025. Growth was led by strong results in the U.S., where we saw 18% year-over-year growth and record revenue in Q2, as well as robust growth in China. These were partially offset by continued softness in EMEA and other APAC, excluding China. Product revenue, which is comprised of instruments and reagents, was $32.6 million, an increase of 4% year-over-year, driven by sales of our high-end instruments, which grew mid-teens during Q2. We saw improved sentiment and strong revenue growth from academic and government customers in the U.S., while biopharma, distributor, and CRO customers grew in other regions. EMEA instrument revenue declined 10% year-over-year, reflecting the government budgetary pressures Wenbin described earlier. In APAC, excluding China, product revenue was also lower, driven by normal fluctuations in purchasing patterns after a strong Q1. Service revenue was $15.6 million, growing 10% year-over-year, driven by our expanding installed base and active instrument utilization globally. By customer segment, biopharma, distributor, and CRO revenue grew approximately 22% year-over-year to $29 million, the result of strong growth in EMEA and China. Academic and government revenue was $19.1 million, down approximately 12% year-over-year. U.S. academic and government revenue grew strongly compared to both prior year Q2 and Q1 of this year. This was offset by weakness in academic and government sectors in EMEA and other APAC, excluding China, after a strong Q1 in both. Turning to slide 9. GAAP gross profit was $28.3 million in Q2, representing a gross margin of 59%, which included a 1-time $2.8 million tariff refund received during the quarter. Excluding that tariff refund, gross margin would have been 53% compared to 52% in Q2 2025. Product gross margin was 60% or 52% excluding the tariff refund, compared to 53% in the year-ago quarter. Service gross margin was 56%, up from 52% in Q2 '25, as a result of lower material costs. Adjusted gross margin, which excludes stock-based compensation and amortization of acquisition-related intangibles, was 61% in the second quarter, or 56% excluding the tariff refund, compared to 56% in the prior year quarter. For subsequent quarters of this year, we expect gross margins, excluding the impact of the tariff refund, to increase as our revenue increases, consistent with our typical seasonal pattern. Total operating expenses were $39.7 million in Q2, up 15% versus Q2 of 2025. Research and development expenses were $9.7 million, up 10% versus Q2 2025, primarily due to higher personnel costs. Sales and marketing expenses were $13.2 million, up 9% versus Q2 2025, primarily due to higher personnel costs, and advertising and marketing expenses. General and administrative expenses were $16.8 million, up $3.3 million, or 24%. The increase was primarily due to higher legal expenses associated with a previously disclosed patent litigation case and higher severance and other personnel costs. Our loss from operations was $11.4 million in the current quarter versus $10.6 million in the year-ago quarter. GAAP net loss in the second quarter was $12.2 million compared to $5.6 million in the prior year quarter. The increase in GAAP net loss was due to 3 factors. First, a higher loss from operations of $0.8 million. Second, a $4.5 million lower net other income, which was primarily due to foreign exchange losses of $0.7 million in the current quarter versus $1.6 million of gains in the year-ago quarter and a $1.6 million non-recurring write-off of an investment in an early-stage technology company. And third, a tax expense of $0.5 million in the current quarter versus $1.2 million of tax benefit in the year-ago quarter. Adjusted EBITDA, which excludes stock-based compensation, foreign exchange impacts, and the non-recurring write-offs, was a loss of $1.5 million in Q2 2026 compared to a positive $1.3 million in Q2 2025. The adjusted EBITDA loss was primarily due to a higher loss from operations, a lower add-back of stock-based comp, and lower investment income. However, we anticipate adjusted EBITDA to improve in the second half as revenue increases with our normal seasonal pattern and operating expense growth moderates. For the full year 2026, we expect to deliver around break-even adjusted EBITDA. Our free cash flow for the quarter was approximately neutral. Cash, cash equivalents, and marketable securities totaled $262 million as of June 30, 2026, compared to $262.2 million as of March 31, 2026. Our balance sheet continues to provide the financial flexibility to invest in our global growth priorities. Turning to slide 10, today we are raising the low end of our full year 2026 revenue guidance range so that the revised range is $207 million to $212 million, increasing the midpoint by $1 million. This assumes no change in currency exchange rates. This outlook reflects positive year-to-date results and the overall growth outlook across our markets, particularly in the U.S. and APAC, including China. In the second half, we expect revenue to be significantly higher in the fourth quarter versus the third, consistent with our typical seasonal revenue patterns. With that, I'll turn it back over to Wenbin. Wenbin Jiang: Thanks, Bill. Turning to slide 11. I want to close by thanking the entire Cytek team for their continuous dedication and execution on behalf of our stakeholders. Our second quarter and first half results reflect the strength of our technology leadership in the flow cytometry industry. Revenue grew 6% year-over-year to $48.1 million in Q2, with strength in the U.S. and China demonstrating the demand for our technology. Our recurring revenue base now represents 35% of trailing 12 months revenue, with service revenue delivering consistent double-digit year-over-year growth, and our reagent business remaining well-positioned to expand. Looking ahead, our priorities remain clear: accelerating the market penetration of our instrument platforms, including the newly launched Borealis and Aurora Evo automation capabilities, advancing our technological leadership through continuous innovation, expanding our recurring revenue line, and delivering profitable, sustainable growth. We believe the investments we have made in our products, our people, and our operations position Cytek well for the remainder of 2026 and for the significant long-term opportunity ahead of us. I want to thank everyone for joining today's call. We will now open up for questions. Operator? Operator: [Operator Instructions] Your first question comes from the line of Brendan Smith with TD Cowen. Brendan Smith: I appreciate all the color on the end market and geographic breakdown in the quarter, especially China and the EU. I guess with the biotech funding environment continuing to improve, should we expect growth across end markets to kind of equilibrate a bit? And I guess just how should we think about levers at your disposal to kind of capitalize on the recovery in the U.S. versus these other geographies? Just any kind of color and relative contribution there would be great. William McCombe: Hi, Brendan. This is Bill. We saw a strong demand, strong momentum in the U.S. driven by academic and government customers in particular. Biopharma in the U.S. was relatively flat, but in the first half, U.S. biopharma was up in the 20% area, so continued to show strong growth on a long-term basis. Europe continued to be a challenged. What we're seeing is that government R&D funding continue to be under pressure as a result of shifting government spending priorities over there and prioritization of other areas such as defense. China was very good in the quarter, and other APAC had a bit of a soft quarter, but we do expect over the longer term that region as a whole will continue to be a strong growth market. In terms of levers, we have significant new products that we talked about, the Borealis, the Aurora Evo automation, with enhanced automation, which are attracting very strong interest from customers. We continue to invest in our sales and marketing infrastructure, and our brand is very strong, and it represents really the leading technology in the space. And that's something that's true in all major markets. Wenbin Jiang: And on top of that, we have seen Cytek cell sorter continue to demonstrate great performance and very well appreciated by our customers and becoming really the workhorse for their daily applications. Operator: Your next question comes from the line of David Westenberg with Piper Sandler. Please go ahead. Skye Gilbert: Hi, this is Skye for Dave. Just first, in the past, I think you've referenced a global installed base of 46,000 flow cytometers as a long-term replacement opportunity. Do you have any visibility into the actual annual replacement or retirement rate, and can you share a bit about the recent instrument placements and whether those have been competitive upgrades from conventional systems or net new full spectrum adoption or expansion within existing full spectrum accounts? And then I have a follow-up. Wenbin Jiang: Based on the market report, the annual placement is between 7,000 to 10,000 within that range. And from Cytek's perspective is, we play primarily in the high end of the research market. Within that market segment and we continue to see great traction with our products, and customers are shifting more and more toward full spectrum technology, which we have outperformed in our space. We believe we are continuing to take market share in that aspect. Skye Gilbert: Okay, great. Thanks. And then just secondly, can you talk a bit more about the dynamics in China? I know you've mentioned China as one of your expanding clinical markets in the past. This quarter you saw double-digit growth. What are you seeing from these China -- Chinese clinical flow cytometry adoption patterns versus kind of what you're seeing in the core academic and government areas? Wenbin Jiang: As you know, we do have our Northern Lights CLC clinically approved for hospital use over there, but just like many other hospital applications actually in other territories, in fact, our research instruments continue to dominate our sales in that market. And I think if you take a look at all the public data around, Cytek continues to be one of the top 3 players in the China market. William McCombe: I just wanted to add something related to the prior question about the replacement opportunity. If you look at the indicators released by -- indicators given in the releases of our competitors, and you look at our growth rate, our growth rate would appear to be significantly higher than our competitors. And one of the factors that could be behind that is the replacement of conventional flow cytometers with FSP, and obviously the strength of our technology and brand position. So I think that our relative growth rate compared to the peers would bear out that, that replacement opportunity is something that's working in our favor. Operator: Your next question comes from the line of Kallum Titchmarsh with Morgan Stanley. Jason Lai: Hi, this is Jason on for Kallum. Maybe just a question on the strategic reorganization to create new business units and align resources to drive growth. Can you just update us where you are from an operational perspective with the reorganization and what remains to be done before being completed in Q3? And how soon could we expect to see benefits from the initiative translate to the P&L? Could benefits start showing up in Q4, and would that represent upside to the 2026 guide? And also, what is the potential for customer disruption just due to changes in the sales force or other factors? William McCombe: So we're in the process of implementing that. As we said, we were going to implement it in Q3, so we've started to do that. I think in terms of the primary objective of this restructuring is to align resources around our different customer segments. As we do that, we expect that to improve our growth rate and improve our -- particularly our market penetration in the mid and low-end instruments and in reagents. So that's the area covered by the solutions business. But look, that's going to take time to really bear significant fruit. The guide that we gave for this year reflects the -- or assumes that this implementation is happening now and will continue. So it's baked into the guide. And I think those are the major points. Wenbin Jiang: I think the way we are structuring, in fact, is going to enable us to serve our customers better because different products are aiming for different customer segments. And then we are able to really focus our resources, our marketing, our sales -- R&D to really optimize our products, our marketing message, aiming for the needs of our customers. So we don't expect any disruption, in fact should make us serving our customers better. William McCombe: So the primary benefit is going to show up in improved top-line growth rate, improved market penetration in the solutions markets, and include an overall improved top-line growth rate. But it will take a little while to show up because those efforts are basically just beginning. Over time, we think this organization will be a significant improver to our growth rate. Jason Lai: Great, thank you. And just to follow up on that, I think the slides mentioned that one of the 3 new business units is a clinical-focused business unit. It mentions that Cytek currently has low share in the clinical market, and the market represents a big growth opportunity. Why do you think flow cytometry is currently underpenetrated in the clinical space today, and what is Cytek's strategy for penetrating the clinical market? Wenbin Jiang: Actually, the business unit is called Solutions and Clinical Business Unit because clinical is part of the solutions. And so overall, and if you look at the pure -- there are 2 parts of the clinical. One is clinical, true diagnostic, that part of the business. Second part is more, kind of, research clinical-oriented business. So we are serving for both markets right now and with what we have developed in particularly the panels, reagents, and as well as the software optimizations to drive the application and penetration into that market across all the territories including China, Europe, as well as the U.S. William McCombe: Yes, what, look, one of the reasons it's a small business for us now is we have approval for clinical product in EMEA and Asia, but we don't have it in the U.S. So that's one of the reasons that we have a small position now and the potential to grow significantly over time. Jason Lai: Appreciate the answers. Congratulations on the quarter. Operator: [Operator Instructions] Your next question comes from the line of Mason Carrico with Stephens, Inc. Harrison Parsons: Hey, this is Harrison on for Mason. Have the assumptions for instruments, service, and reagents baked into the guide shifted at all? Expectations as of last quarter were for continued growth in services and reagent revenue at levels consistent with recent quarters and flat to modest growth in instruments. Does that framework still hold within the updated guidance framework today? William McCombe: Yes, generally, that's true. Look, every quarter we look at the results and we tweak the framework. But our service business grew 10%. We would expect continued growth at that level or better in services. So I think no major changes. The instrument revenues grew, frankly, a little towards the higher end of our range of assumptions. So we look at the quarter and various scenarios and come up with the range based on looking at a range of scenarios. And I would say there aren't major changes to that framework. Harrison Parsons: And then when you initially set the guide in February, you described a contingency built in for unforeseen macro developments. Has any of that cushion been consumed in the first half? And what's the dollar figure for that cushion in the back half if there's -- if it's still being assumed into the guidance? William McCombe: Yes, look, there's some contingency there. We don't break it out. It's not a -- there's not one formula with specific numbers that we use to produce the guide. It's not a formulaic or mechanical calculation. We look at a number of scenarios, and there's some contingency in the back half there. You'll note that grown faster in the first half than would be implied, certainly by the low end of our guide, and even the midpoint of the guide. And so you can conclude from that, that we still have some contingency in our number. We're not seeing any -- we're not forecasting any change in our markets. Operator: There are no further questions at this time. Ladies and gentlemen, thank you for joining today's conference call. You may disconnect. Before you buy stock in Cytek Biosciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cytek Biosciences wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $403,337!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,334,946!* That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul. See the 10 stocks » *Stock Advisor returns as of August 12, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Cytek (CTKB) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Performance was primarily driven by strong double-digit revenue growth in the U.S. and China, alongside mid-teens growth in the high-end FSP instrument portfolio. U.S. growth of 18% reflects robust instrument demand within the academic and government sectors, maintaining momentum from the first quarter. EMEA revenue declined approximately 8% as regional geopolitical dynamics continue to exert pressure on government R&D and budgetary priorities. The service business delivered consistent 10% growth, fueled by an expanding installed base and high global instrument utilization rates. Management attributes market share gains to the ongoing industry shift where customers are replacing conventional flow cytometers with Full Spectrum Profiling (FSP) technology. The launch of the Borealis 60-color system and Aurora Evo automation enhancements aim to extend technology leadership by improving laboratory throughput and biomarker resolution. Full-year revenue guidance was raised at the low end to $207 million to $212 million, reflecting positive year-to-date momentum and a strong U.S. outlook. Management expects a significant seasonal revenue weighting toward the fourth quarter, consistent with historical purchasing patterns. The company is transitioning to three customer-aligned business units in Q3 2026 to better focus R&D and sales resources on specific market segments. Adjusted EBITDA is projected to reach approximately break-even for the full year as seasonal revenue increases and operating expense growth moderates in the second half. Recurring revenue is expected to represent an increasing percentage of total revenue, supported by high utilization and the growth of the Cytek Cloud ecosystem. Gross margins were positively impacted by a one-time $2.8 million tariff refund; excluding this, gross margin improved to 53% from 52% year-over-year. GAAP net loss widened due to a $1.6 million non-recurring write-off of an investment in an early-stage technology company and unfavorable foreign exchange swings. General and administrative expenses rose 24%, driven by higher legal costs related to patent litigation and personnel-related severance charges. Geopolitical dynamics in EMEA remain a headwind, specifically impacting government R&D funding as spending shifts toward defense. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management expects the reorganization to improve market penetration in mid-to-low end instruments and reagents by aligning resources with specific customer needs. The 2026 guidance already accounts for the implementation phase, with significant top-line benefits expected to materialize over the longer term rather than immediately in Q4. The shift is intended to enhance customer service through specialized marketing and R&D, with no anticipated disruption to existing sales operations. Cytek's growth rate appears significantly higher than competitors, which management believes validates their success in replacing conventional flow cytometers with FSP technology. The annual market placement for flow cytometers is estimated between 7,000 to 10,000 units, with Cytek focusing on the high-end research segment. The clinical business currently represents a small portion of revenue due to a lack of U.S. clinical approval, though products are approved in EMEA and Asia. In China, while clinical-grade instruments are available, research-grade instruments still dominate sales for hospital applications.

This article first appeared on GuruFocus. Revenue: $48.1 million in Q2 2026, up 6% year-over-year. Product Revenue: $32.6 million, up 4% year-over-year, driven by high-end instrument sales. Service Revenue: $15.6 million, up 10% year-over-year. Gross Margin (GAAP): 59%, including a one-time $2.8 million tariff refund; 53% excluding the refund. Product Gross Margin: 60% (52% excluding tariff refund). Service Gross Margin: 56%, up from 52% in Q2 2025. Operating Expenses: $39.7 million, up 15% year-over-year. R&D Expenses: $9.7 million, up 10% year-over-year. Sales and Marketing Expenses: $13.2 million, up 9% year-over-year. G&A Expenses: $16.8 million, up 24% year-over-year. Loss from Operations: $11.4 million, compared to $10.6 million in Q2 2025. GAAP Net Loss: $12.2 million, compared to $5.6 million in the prior year quarter. Adjusted EBITDA: Loss of $1.5 million, compared to positive $1.3 million in Q2 2025. Free Cash Flow: Approximately neutral for the quarter. Cash and Marketable Securities: $262 million as of June 30, 2026. Installed Base: Added 142 units, bringing total to 3,933 units. Recurring Revenue: Combined reagents and service revenue was $18.5 million, up 8% year-over-year, representing 35% of last 12-month revenue. Full Year 2026 Revenue Guidance: Raised to $207 million to $212 million. Warning! GuruFocus has detected 5 Warning Signs with CTKB. Is CTKB fairly valued? Test your thesis with our free DCF calculator. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Cytek Biosciences Inc (NASDAQ:CTKB) delivered solid Q2 2026 revenue growth of 6% year-over-year, reaching $48.1 million, driven by strong double-digit growth in the US and China. The company's high-end FSP instrument portfolio grew 11% year-over-year, led by strong sales of the Aurora Evo Analyzer and Aurora CS systems. Cytek Biosciences Inc (NASDAQ:CTKB) launched the Borealis, the industry's first 60-color, seven-laser full spectral flow cytometer, which has received very strong feedback from early access customers. The recurring revenue base (reagents and services) strengthened, growing 8% year-over-year to $18.5 million and now representing 35% of last 12-month revenue, up from 32% in the prior year period. The company raised the low end of its full-year 2026 revenue guidance to $207 million-$212 million, reflecting positive year-to-date results and a strong growth outlook, particularly in the US and APAC. Cytek Biosciences Inc (NASDAQ:CTKB) maintains a strong balance sheet with $262 million in cash and marketable securities, providing financial flexibility for investment in growth priorities. Cytek Biosciences Inc (NASDAQ:CTKB) experienced continued softness in EMEA, with revenue down approximately 8% year-over-year due to ongoing government budgetary pressures from regional geopolitical dynamics. Total APAC revenue, excluding China, was flat year-over-year, with softness in other parts of the region offsetting strong growth in China. GAAP net loss widened to $12.2 million in Q2 2026 from $5.6 million in the prior year quarter, impacted by higher operating losses, foreign exchange losses, and a non-recurring investment write-off. Adjusted EBITDA turned negative at a loss of $1.5 million in Q2 2026, compared to a positive $1.3 million in Q2 2025, due to higher operating expenses and lower investment income. Academic and government revenue declined 12% year-over-year to $19.1 million, as strong US growth was offset by weakness in EMEA and other APAC regions. The company's strategic reorganization into three business units is expected to take time to yield significant benefits, with the full impact on growth not expected to materialize immediately. Q: With the biotech funding environment improving, should we expect growth across end markets to equilibrate, and what levers are available to capitalize on recovery in the U.S. versus other geographies? A: CFO William Mccombe noted strong U.S. momentum driven by academic and government customers, while U.S. biopharma was relatively flat in Q2 but up ~20% in the first half. Europe remains challenged due to government R&D funding pressure from shifting spending priorities toward defense. China was strong, and other APAC had a soft quarter but is expected to remain a growth market long-term. Levers include new products like Borealis and Aurora Evo automation, continued investment in sales/marketing infrastructure, and a strong brand position as the leading technology in the space. Q: What is the annual replacement or retirement rate for the global installed base of 46,000 flow cytometers, and are recent instrument placements competitive upgrades from conventional systems, net new full-spectrum adoption, or expansion within existing accounts? A: CFO William Mccombe cited market reports indicating annual placements of 7,000 to 10,000 units. Cytek plays primarily in the high-end research market, where customers are increasingly shifting toward full-spectrum technology, and the company believes it is continuing to take market share. CEO Wenbin Jiang added that Cytek's growth rate is significantly higher than competitors, suggesting the replacement of conventional cytometers with FSP is working in the company's favor. Q: Can you provide more detail on the dynamics in China, particularly regarding clinical flow cytometry adoption versus core academic and government areas? A: CFO William Mccombe noted that while Cytek has its Northern Lights instrument clinically approved for hospital use in China, research instruments continue to dominate sales in that market. He highlighted that Cytek remains one of the top three players in the China market based on public data. Q: Where are you from an operational perspective with the strategic reorganization into three business units, and how soon could benefits translate to the P&L? What is the potential for customer disruption? A: CEO Wenbin Jiang stated the reorganization is in process and expected to be implemented in Q3. The primary objective is aligning resources around different customer segments to improve growth rates and market penetration, particularly in mid/low-end instruments and reagents. Benefits will take time to materialize and are already baked into the 2026 guidance. CFO William Mccombe added that the restructuring should enable better customer service through focused resources and marketing, with no expected disruption. Q: Why is flow cytometry currently underpenetrated in the clinical space, and what is Cytek's strategy for penetrating the clinical market? A: CFO William Mccombe explained the business unit is called "Solutions and Clinical" because clinical is part of the solutions segment. Cytek serves both true diagnostic and research-clinical markets with panels, reagents, and software optimizations across China, Europe, and the U.S. CEO Wenbin Jiang added that the clinical business is currently small partly because Cytek has approval for clinical products in EMEA and Asia but not yet in the U.S., representing significant potential for future growth. Q: Have the assumptions for instrument, service, and reagent revenue baked into the guidance shifted from last quarter's framework of continued growth in services/reagents and flat-to-modest growth in instruments? A: CEO Wenbin Jiang confirmed the framework generally holds, with service revenue growing 10% and expected to continue at that level or better. Instrument revenue grew toward the higher end of assumptions. The guidance range is based on a range of scenarios with no major changes to the framework. Q: Has any of the contingency cushion built into the February guidance been consumed in the first half, and what is the dollar figure for the back half if still assumed? A: CEO Wenbin Jiang stated there is still some contingency in the back half, though the company does not break it out or use a formulaic calculation. He noted the company is growing faster in the first half than implied by the low end or even midpoint of guidance, indicating contingency remains. No changes in market conditions are being forecast. Q: Can you elaborate on the performance of the newly launched Borealis system and the Aurora Evo automation capabilities, and how they are being received by customers? A: CEO Wenbin Jiang highlighted the Borealis as the industry's first 60-color, seven-laser full-spectral flow cytometer, enabled by proprietary deep UV and IR reagents. It expands cellular biomarker analysis, improves efficiency with nanoparticle analysis and high flow rates, and allows integration of high-parameter cellular imaging. Feedback from early access customers has been very strong. The Aurora Evo configurations add automated and remote operation with an API for interfacing with automation systems, particularly relevant for biopharma and CROs. Q: What drove the strong U.S. performance in Q2, and how sustainable is this growth across different customer segments? A: CFO William Mccombe reported U.S. revenue of $28.2 million, up 18% year-over-year, driven by impressive growth in equipment revenue from academic and government sectors and the service business. Biopharma in the U.S. was relatively flat in Q2 but up ~20% in the first half, indicating continued strong longer-term growth. The company expects the U.S. to remain a key growth driver. Q: How is the recurring revenue base evolving, and what is the outlook for service and reagent revenue as a percentage of total revenue? A: CFO William Mccombe noted combined reagent and service revenue was $18.5 million in Q2, up 8% year-over-year, representing 35% of last-12-month revenue, up from 32% a year ago. Service revenue grew 10% to $15.6 million, driven by the expanding installed base and high instrument utilization. The company expects recurring revenue to represent an increasing percentage of total revenue over time. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Interested in Cytek Biosciences, Inc.? Here are five stocks we like better. Revenue increased 6% year over year to $48.1 million, driven by 18% U.S. growth, strong China performance, and gains in full spectrum profiling instruments and services. Weakness in Europe and parts of Asia-Pacific restrained overall results. Cytek expanded its installed base to 3,933 instruments and increased recurring revenue, with combined reagent and service revenue up 8% to $18.5 million. The company also launched the 60-color Borealis cytometer and more automated Aurora Evo configurations. Profitability weakened: GAAP net loss widened to $12.2 million from $5.6 million, while adjusted EBITDA turned negative at $1.5 million. Despite the loss, Cytek raised its 2026 revenue outlook to $207 million–$212 million and continues to target roughly breakeven adjusted EBITDA for the full year. Cytek Biosciences (NASDAQ:CTKB) reported second-quarter 2026 revenue growth of 6% year over year, supported by double-digit gains in the United States and China, while continued weakness in Europe and parts of Asia-Pacific limited overall growth. Revenue for the quarter ended June 30 was $48.1 million, compared with $45.6 million a year earlier. CEO Wenbin Jiang said performance was driven by U.S. and China growth, gains in the company’s full spectrum profiling, or FSP, instrument portfolio, and continued expansion in service revenue. → SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control U.S. revenue rose 18% from the prior-year period to $28.2 million, marking record second-quarter revenue in the region, according to CFO Bill McCombe. The growth reflected increased instrument sales to academic and government customers as well as service-business growth. Revenue in Europe, the Middle East and Africa totaled $11.3 million, down about 8% year over year. Management attributed the decline to budgetary constraints tied to regional geopolitical dynamics and shifting government spending priorities. McCombe said European government research-and-development funding remained under pressure, including as governments prioritized areas such as defense. → 3 Drone Stocks That Should Soar After the Summer Slump Total APAC revenue, including China, was $7.9 million and was flat year over year. China delivered strong double-digit growth against a modest comparison period, but that performance was offset by softness elsewhere in the region. McCombe said purchasing patterns in APAC excluding China were lower following a strong first quarter. By customer category, revenue from biopharma, distributors and contract research organizations rose approximately 22% to $29 million, aided by growth in EMEA and China. Academic and government revenue declined approximately 12% to $19.1 million, as U.S. growth was more than offset by declines in EMEA and other APAC markets. → The Bitcoin Comeback May Already Be Underway—2 ETFs for Exposure Cytek added 142 instrument units during the quarter, increasing its global installed base to 3,933 units. Its high-end FSP portfolio grew 11% year over year, led by the Aurora Evo Analyzer and Aurora CS Cell Sorter. Product revenue, which includes instruments and reagents, increased 4% to $32.6 million. Sales of high-end instruments rose by a mid-teens percentage during the quarter, the company said. Recurring revenue continued to account for a larger share of the company’s business. Combined reagent and service revenue reached $18.5 million, up 8% year over year, and represented 35% of revenue over the trailing 12 months, compared with 32% in the comparable prior-year period. Service revenue increased 10% to $15.6 million, supported by the larger installed base and active utilization of instruments globally. Jiang said the company expects recurring revenue to become a greater percentage of total revenue over time. The company also said Cytek Cloud, its bioinformatics platform, surpassed 28,000 users as of June 30, up 15% since the start of the year. Jiang said the platform supports researchers developing experiment workflows and can contribute to customer engagement and adoption of Cytek’s reagent and service offerings. Cytek introduced the Borealis, which it described as the industry’s first 60-color, seven-laser, full spectral-flow cytometer. The system is designed to enable analysis of 60 unique colors in one sample run and can analyze nanoparticles, operate at higher flow rates and support enhanced automation, according to the company. Jiang said the Borealis has also been designed to support future integration of onboard high-parameter cellular imaging capabilities. He said feedback from early-access customers has been “very strong,” with broader commercial availability expected to progress over time. The company also launched new Aurora Evo configurations with expanded automation functions, including remote operation of certain instrument functions and an application programming interface for automated plate-handling systems. Management said those capabilities are particularly relevant to biopharma organizations and CROs seeking efficiency, reproducibility and laboratory-system integration. During the question-and-answer session, Jiang said the annual market placement opportunity for flow cytometers is between 7,000 and 10,000 units, based on market reports. He said customers have increasingly shifted toward full spectral technology and that Cytek believes it is gaining share in the higher-end research segment. GAAP gross profit was $28.3 million, or a 59% gross margin, including a one-time $2.8 million tariff refund. Excluding the refund, gross margin would have been 53%, compared with 52% in the year-earlier quarter. Service gross margin improved to 56% from 52%, which management attributed to lower material costs. Operating expenses increased 15% to $39.7 million. General and administrative spending rose 24%, primarily because of legal expenses related to previously disclosed patent litigation, severance costs and other personnel expenses. The company reported a GAAP net loss of $12.2 million, compared with a $5.6 million net loss a year earlier. McCombe cited a higher operating loss, lower other income, foreign-exchange losses, a $1.6 million non-recurring write-off of an investment in an early-stage technology company, and tax expense versus a prior-year tax benefit. Adjusted EBITDA was a loss of $1.5 million, compared with positive adjusted EBITDA of $1.3 million in the prior-year quarter. Management expects adjusted EBITDA to improve in the second half as revenue follows its typical seasonal pattern and operating-expense growth moderates. Cytek continues to expect roughly breakeven adjusted EBITDA for full-year 2026. Cash, cash equivalents and marketable securities totaled $262 million as of June 30, essentially unchanged from $262.2 million at March 31. Free cash flow was approximately neutral for the quarter. Cytek raised the low end of its full-year revenue outlook and now expects 2026 revenue of $207 million to $212 million, increasing the midpoint by $1 million. The outlook assumes no currency-rate changes and calls for fourth-quarter revenue to be significantly higher than third-quarter revenue, consistent with the company’s historical seasonal pattern. The company is also implementing an organizational structure during the third quarter centered on three customer-aligned units: Solutions and Clinical, Research Technology, and Service. McCombe said the primary expected benefit is improved top-line growth and deeper market penetration, though he said the effects will take time and are already incorporated into the company’s 2026 guidance. Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods. The company's core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Cytek Biosciences Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

FREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights Total revenue for the second quarter of 2026 was $48.1 million, representing a 6% increase compared to the second quarter of 2025 Launched Cytek Borealis™, a new 7-laser full spectrum flow cytometer with new and proprietary reagents enabling high-resolution 60-color panels Introduced Cytek Aurora™ Evo instrument configurations with expanded automation capabilities for highly automated lab environments Total recurring revenue, comprised of service and reagent revenues, reached $18.5 million in the second quarter. On a trailing-12-month basis, recurring revenue represented 35% of total revenue, up from 32% on a trailing-12-month basis as of the second quarter of 2025 Expanded to a total installed base of 3,933 Cytek instruments, adding 142 units in the second quarter of 2026 Updates full year 2026 total revenue guidance to $207 million to $212 million, raising the midpoint by $1 million “Our second quarter results reflect continued execution against our strategic priorities, exemplified by strong double-digit revenue growth in instruments in the U.S. and in China and ongoing and consistent expansion of our service business,” said Wenbin Jiang, CEO of Cytek Biosciences. “Looking ahead, our priorities remain clear: accelerating adoption of our instrument platforms, including newly launched instruments, expanding recurring revenue business and extending our technology leadership. We believe our investments in products, people, and operations position Cytek well for the remainder of 2026 and the long-term opportunity ahead.” Second Quarter 2026 Financial Results Total revenue for the second quarter of 2026 was $48.1 million, a 6% increase compared to the second quarter of 2025. The increase in revenue was driven by strong instrument growth in the U.S. and in China, and continued growth in service. GAAP gross profit was $28.3 million for the second quarter of 2026, a 19% increase compared to the second quarter of 2025. GAAP gross profit margin was 59% in the second quarter of 2026 compared to 52% in the second quarter of 2025. Adjusted gross profit margin, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles, was 61% in the second quarter of 2026 compared to 56% in the second quarter of 2025. Excluding the impact of a one-time tariff refund, GAAP and adjusted gross margin in the second quarter of 2026 were 53% and 56%, respectively. Operating expenses were $39.7 million for the second quarter of 2026, a 15% increase compared to the second quarter of 2025 due to increased research and development, sales and marketing, and general and administrative expenses. Research and development expenses were $9.7 million for the second quarter of 2026, a 10% increase compared to the second quarter of 2025. Sales and marketing expenses were $13.2 million for the second quarter of 2026, a 9% increase compared to the second quarter of 2025. General and administrative expenses were $16.8 million for the second quarter of 2026, a 24% increase compared to the second quarter of 2025 due to litigation-related expenses, severance and personnel costs. Loss from operations in the second quarter of 2026 was $11.4 million compared to loss from operations of $10.6 million in the second quarter of 2025. Net loss in the second quarter of 2026 was $12.2 million compared to a net loss of $5.6 million in the second quarter of 2025. Adjusted EBITDA loss in the second quarter of 2026 was $1.5 million compared to positive adjusted EBITDA of $1.3 million in the second quarter of 2025, after adjusting for stock-based compensation expense, foreign currency exchange impacts and a write-off of an investment in an early-stage technology company. Cash, cash equivalents and marketable securities totaled $262.0 million as of June 30, 2026, compared to $262.2 million as of March 31, 2026, a decrease of $0.2 million. 2026 Outlook Cytek Biosciences is updating its revenue outlook for the full year 2026 to be in the range of $207 million to $212 million, raising the midpoint by $1 million, assuming no change in current foreign currency exchange rates. Webcast Information Cytek will host a conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com. Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Cytek Borealis, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution for information about the company, its products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Certain information disseminated through these channels may be material to investors, and Cytek may use these channels to disseminate such information in accordance with Regulation FD and other applicable disclosure requirements. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Statement Regarding Use of Non-GAAP Financial Information Cytek has presented certain financial information in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and also on a non-GAAP basis for the three-month period ended June 30, 2026 and June 30, 2025. Management believes that non-GAAP financial measures, including “Adjusted gross profit,” “Adjusted gross profit margin,” “Adjusted EBITDA” and “Adjusted EBITDA excluding investment income,” referenced in this release, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, without limitation, statements regarding Cytek’s business strategies, market opportunities, product plans and expectations, and continued investment in its products, people, and infrastructure; Cytek’s expanding installed base and future recurring revenue growth in its service and reagent businesses; and Cytek’s future financial performance, including its outlook for fiscal year 2026 and expectations for 2026 total revenue. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek’s ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section titled “Risk Factors” set forth in Cytek’s most recent Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, Cytek’s Quarterly Report on Form 10-Q to be filed with the SEC on or about the date hereof and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are applicable only as of the date on which they are made, and Cytek does not assume any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only. Media Contact:Stephanie OlsenLages & Associates(949) [email protected] Investor Contact:Mark MeehanCytek [email protected]

The market expects Kyntra Bio (KYNB) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This biotech drug developer is expected to post quarterly loss of $3.18 per share in its upcoming report, which represents a year-over-year change of +5.9%. Revenues are expected to be $1.99 million, up 47.4% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 1.62% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Kyntra Bio, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +5.44%. On the other hand, the stock currently carries a Zacks Rank of #3. So, this combination indicates that Kyntra Bio will most likely beat the consensus EPS estimate. Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Kyntra Bio would post a loss of$3.36 per share when it actually produced a loss of -$3.74, delivering a surprise of -11.31%. Over the last four quarters, the company has beaten consensus EPS estimates two times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Kyntra Bio appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Cytek Biosciences, Inc. (CTKB), is soon expected to post loss of $0.02 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of -300%. This quarter's revenue is expected to be $47.36 million, up 3.9% from the year-ago quarter. The consensus EPS estimate for Cytek Biosciences has been revised 50% higher over the last 30 days to the current level. However, an equal Most Accurate Estimate has resulted in an Earnings ESP of 0.00%. This Earnings ESP, combined with its Zacks Rank #2 (Buy), makes it difficult to conclusively predict that Cytek Biosciences will beat the consensus EPS estimate. Over the last four quarters, the company surpassed EPS estimates just once. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kyntra Bio Inc (KYNB) : Free Stock Analysis Report Cytek Biosciences, Inc. (CTKB) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

The market expects Cytek Biosciences, Inc. (CTKB) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 5, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. This company is expected to post quarterly loss of $0.02 per share in its upcoming report, which represents a year-over-year change of -300%. Revenues are expected to be $47.36 million, up 3.9% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 50% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Cytek Biosciences, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%. On the other hand, the stock currently carries a Zacks Rank of #2. So, this combination makes it difficult to conclusively predict that Cytek Biosciences will beat the consensus EPS estimate. While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Cytek Biosciences would post a loss of$0.08 per share when it actually produced a loss of -$0.12, delivering a surprise of -50.00%. Over the last four quarters, the company has beaten consensus EPS estimates just once. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Cytek Biosciences doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Gilead Sciences (GILD), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report loss per share of $7.07 for the quarter ended June 2026. This estimate points to a year-over-year change of -451.7%. Revenues for the quarter are expected to be $7.37 billion, up 4% from the year-ago quarter. Over the last 30 days, the consensus EPS estimate for Gilead has been revised 1.6% down to the current level. Nevertheless, the company now has an Earnings ESP of -0.75%, reflecting a lower Most Accurate Estimate. This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Gilead will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cytek Biosciences, Inc. (CTKB) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

FREMONT, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the second quarter of 2026 after market close on Wednesday, August 5, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc.Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com. Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution for information about the company, its products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Certain information disseminated through these channels may be material to investors, and Cytek may use these channels to disseminate such information in accordance with Regulation FD and other applicable disclosure requirements. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Media Contact:Stephanie OlsenLages & Associates(949) [email protected] Investor Contact:Mark MeehanCytek [email protected]

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. U.S. revenue rebounded 32% year-over-year, signaling a return to normal market conditions and strong demand from repeat academic and biopharma buyers. Management is restructuring the company into three distinct business units—Solutions and Clinical, Research Technology, and Service—to better align R&D and sales with specific customer workflows. Recurring revenue reached 35% of total revenue, driven by a 19% increase in service and reagents as the growing installed base of 3,789 units fuels active utilization. EMEA performance was hindered by geopolitical conflict in the Middle East and specific end-of-quarter shipment delays, resulting in a 7% revenue decline. APAC results were impacted by difficult year-over-year comparisons in China due to accelerated order timing in Q1 2025, though the broader region continues to show secular growth. The Aurora Evo system is driving volume growth by addressing biopharma needs for higher throughput, integrated automation, and nanoparticle detection. Full-year 2026 revenue guidance of $205 million to $212 million is reaffirmed, assuming stable currency rates and continued momentum in the U.S. and APAC. The guidance framework assumes steady growth in services and reagents with flat to modest growth in instruments, including a contingency for unforeseen macro risks. Management expects to achieve positive adjusted EBITDA for the full year 2026, driven by typical seasonal revenue acceleration in subsequent quarters. The operational refocus into three business units is scheduled for completion in the third quarter of 2026 to accelerate market share gains in the clinical and low-to-mid tier instrument segments. Gross margins are expected to increase in the coming quarters as revenue scales, following the company's historical seasonal patterns. General and administrative expenses rose 43% primarily due to higher legal costs associated with ongoing patent litigation and increased bad debt reserves. Net loss widened to $18.9 million, impacted by a $1.2 million foreign exchange loss compared to a gain in the prior year period. Service gross margins were slightly pressured by higher labor costs, though overall adjusted gross margin remained relatively stable at 51%. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Reaching the high end depends on maintaining current growth trajectories in services and reagents while navigating a cautious instrument market. The lower end of the range accounts for potential macro risks and unforeseen global disruptions that management cannot currently predict. Management reported that U.S. academic and government demand was exceptionally strong in Q1, reaching one of its highest levels ever despite budget discussions. The current administration's budget proposals are viewed as less 'draconian' than previous years, providing a more stable outlook for academic disbursements. The Q1 customer mix shifted toward biopharma and CROs at 62%, compared to 38% for academic and government. The Aurora Evo is seeing strong reception in both segments, though its automated features and high throughput were specifically designed to solve biopharma workflow challenges.

FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Total revenue for the first quarter of 2026 was $44.1 million, representing a 6% increase compared to the first quarter of 2025 Service revenue for the first quarter of 2026 was $15.4 million, representing a 15% increase compared to the first quarter of 2025 Total recurring revenue, comprised of service and reagent revenues, reached $18.4 million in the first quarter. On a trailing-12-month basis, recurring revenue represented 35% of total revenue, up from 31% on a trailing-12-month basis as of the first quarter of 2025 Expanded to a total installed base of 3,789 Cytek instruments, adding 125 units in the first quarter of 2026 “Our first quarter growth stands out in a market that continues to experience global challenges, underscoring Cytek’s technology leadership, the growth of our installed base, and the expansion of our recurring revenue streams,” said Wenbin Jiang, CEO of Cytek Biosciences. “Rising instrument placements are expanding our installed base and driving higher demand for reagents and service, making recurring revenue an increasing share of total revenue. With focused execution and continued investment in our products, people, and infrastructure, we are well positioned for the year ahead.” First Quarter 2026 Financial Results Total revenue for the first quarter of 2026 was $44.1 million, a 6% increase compared to the first quarter of 2025. The increase in revenue was driven by strong revenue performance in the US and continued growth in service and reagent revenue worldwide. GAAP gross profit was $21.3 million for the first quarter of 2026, a 5% increase compared to the first quarter of 2025. GAAP gross profit margin was 48% in the first quarter of 2026 compared to 49% in the first quarter of 2025. Adjusted gross profit margin, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles, was 51% in the first quarter of 2026 compared to 52% in the first quarter of 2025. Operating expenses were $39.7 million for the first quarter of 2026, a 13% increase compared to the first quarter of 2025 due to increased general and administrative expenses, partially offset by a reduction in sales and marketing and research and development expenses. Research and development expenses were $9.6 million for the first quarter of 2026, a 1% decrease compared to the first quarter of 2025. Sales and marketing expenses were $11.6 million for the first quarter of 2026, a 7% decrease compared to the first quarter of 2025. General and administrative expenses were $18.5 million for the first quarter of 2026, increasing 43% compared to the first quarter of 2025 due primarily to litigation-related expenses, outside consulting expenses and bad debt reserves. Loss from operations in the first quarter of 2026 was $18.5 million compared to loss from operations of $15.0 million in the first quarter of 2025. Net loss in the first quarter of 2026 was $18.9 million compared to a net loss of $11.4 million in the first quarter of 2025. Adjusted EBITDA loss in the first quarter of 2026 was $9.1 million compared to an adjusted EBITDA loss of $3.3 million in the first quarter of 2025, after adjusting for stock-based compensation expense and foreign currency exchange impacts. Cash and marketable securities totaled $262.2 million as of March 31, 2026 compared to $261.5 million as of December 31, 2025, an increase of $0.7 million. 2026 Outlook Cytek Biosciences reaffirms its 2026 revenue guidance to be in the range of $205 million to $212 million, representing growth of 2% to 5% over full year 2025, assuming no change from current currency exchange rates. Webcast Information Cytek will host a conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com. Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Statement Regarding Use of Non-GAAP Financial Information Cytek has presented certain financial information in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and also on a non-GAAP basis for the three-month period ended March 31, 2026 and March 31, 2025. Management believes that non-GAAP financial measures, including “Adjusted gross profit,” “Adjusted gross profit margin,” and “Adjusted EBITDA loss,” referenced in this release, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, without limitation, statements regarding Cytek’s expanding installed base and future recurring revenue growth in its service and reagent businesses; Cytek’s business strategy and continued investment in its products, people, and infrastructure; Cytek’s market opportunities; and Cytek’s future financial performance, including its outlook for fiscal year 2026 and expectations for 2026 total revenue. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek’s ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section titled “Risk Factors” set forth in Cytek’s most recent Annual Report on Form 10-K filed with the SEC on February 26, 2026, Cytek’s Quarterly Report on Form 10-Q to be filed with the SEC on or about the date hereof and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release and the related conference call, webcast and presentation are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only. Media Contact: Stephanie Olsen Lages & Associates (949) 453-8080 [email protected] Investor Contact: Paul Goodson Head of Investor Relations Cytek Biosciences [email protected]

Interested in Cytek Biosciences, Inc.? Here are five stocks we like better. Cytek reported Q1 2026 revenue of $44.1 million, up 6% year-over-year, driven by a 32% rebound in the U.S., rising recurring revenue (reagents and service), and continued demand for the Aurora Evo as the installed base grew by 125 units to 3,789. Profitability was pressured as GAAP net loss widened to $18.9 million and adjusted EBITDA was a $9.1 million loss, with operating expenses up 13% and G&A rising 43% primarily due to patent litigation, though management expects seasonal improvement and positive adjusted EBITDA for full-year 2026. Management reaffirmed full-year revenue guidance of $205–$212 million and plans a Q3 reorganization into three customer-aligned business units to better target reagent, clinical, and mid‑tier instrument opportunities. Cytek Biosciences (NASDAQ:CTKB) reported first-quarter 2026 revenue of $44.1 million, up 6% from $41.5 million in the year-ago quarter, as strength in the U.S. and continued growth in recurring revenue helped offset softer results in EMEA and APAC. Management characterized the quarter as a “constructive start to the year” and pointed to what CEO Wenbin Jiang described as “a return to normal market conditions in the U.S.” despite ongoing challenges across the broader life science tools industry. Jiang said Cytek’s performance reflected “continued positive momentum from the second half of 2025,” supported by secular growth in APAC excluding China, globally rising recurring revenue, and portfolio diversity. He also highlighted demand for the company’s Aurora Evo system, which launched last year, and said the installed base continues to drive expansion in service and leasing. → Berkshire Hathaway’s Record Cash Hoard: Why and What's Next? By geography, Cytek’s U.S. revenue rose 32% year-over-year to $24.4 million. Jiang said performance in the U.S. was “broad-based” and included sales to academic institutions and biopharma companies, with a high percentage of buyers having purchased at least one instrument in the prior four quarters. EMEA revenue fell 7% to $10.8 million, with Jiang attributing softer instrument revenue to disruption from the conflict in the Middle East and an end-of-quarter shipment delay in another region, partially offset by continued service growth. APAC, including China, declined 13% year-over-year due primarily to accelerated order timing in China in the first quarter of 2025, though Jiang said APAC excluding China delivered “very strong growth across instruments, reagents, and service.” Recurring revenue continued to rise. Jiang said combined reagents and service revenue reached $18.4 million in the quarter and represented 35% of total revenue on a trailing 12-month basis, up 19% year-over-year. Service revenue grew 15% year-over-year to $15.4 million, which management linked to installed base growth and active instrument utilization. Jiang added that reagent revenue grew in the mid-teens year-over-year, also reflecting usage of the installed base. → A Prada Payday: Is AMC Back in Style? Cytek added 125 units in the first quarter, bringing total installed base to 3,789 units, according to Jiang. Total instrument unit volume increased 9% year-over-year, including a 3% increase in SSP instruments. Jiang said revenue for the Aurora category increased 8% year-over-year and that the Aurora Evo system has “consistently driven revenue and unit volume growth” since its introduction. On the reagent side, Jiang reported 16% growth versus the first quarter of 2025, calling the strength “broad-based across regions.” He said APAC and the rest-of-world regions together grew reagent revenue by more than 40% year-over-year, with double-digit growth in the U.S. Jiang tied the performance to initiatives undertaken in 2025, including improved delivery times, expanded offerings, and a dedicated reagent sales team. → Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30% The company also pointed to continued adoption of its bioinformatics platform. Jiang said Cytek Cloud surpassed 26,000 users as of March 31, 2026, representing an average of eight users per installed Cytek SSP instrument, and said growing usage strengthens the value proposition of an integrated ecosystem. Jiang said Cytek plans to refocus operations into three customer-aligned business units, a change expected to be completed in the third quarter of 2026. The new Solutions and Clinical business unit will include platforms such as reagents, Guava Muse Micro, and Northern Lights, while the Research Technology business unit will focus on high-parameter flow cytometry in the research-use-only market. A separate Service business unit is intended to support the installed base across both operating groups. Jiang said the new structure is intended to better align marketing, sales, and R&D resources and to pursue opportunities including reagent consumables and low- to mid-tier instruments for QA/QC workflows, as well as an eventual replacement cycle for high-performance instruments. He also said Cytek sees “meaningful growth opportunities in the clinical research market,” noting that the increase is “already being reflected by an increase in reagent sales supporting clinical applications.” CFO Bill McCombe reiterated first-quarter revenue of $44.1 million and said growth was led by strong U.S. instrument performance alongside double-digit growth in global services and reagents, partially offset by EMEA disruption and APAC order timing. Product revenue (instruments and reagents) totaled $28.8 million, up about 2% year-over-year, while service revenue was $15.4 million, up 15%. GAAP gross profit was $21.3 million, and gross margin was 48%, down from 49% a year earlier. McCombe said product gross margin was flat, while service gross margin was “slightly lower due to higher labor costs.” Adjusted gross margin was 51% compared with 52% in the prior-year quarter. Looking ahead, McCombe said the company expects gross margins to increase in subsequent quarters as revenue rises “consistent with our typical seasonal pattern.” Operating expenses increased 13% year-over-year to $39.7 million. R&D declined 1% to $9.6 million due to lower compensation expenses, and sales and marketing fell 7% to $11.6 million, also tied to lower compensation and selling commissions. General and administrative expense rose 43% to $18.5 million, driven primarily by “higher legal expenses associated with a previously disclosed patent litigation case,” outside consulting expenses, and bad debt reserves. Loss from operations was $18.5 million versus $15.0 million a year earlier. GAAP net loss widened to $18.9 million from $11.4 million, which McCombe attributed to higher operating expenses, a $1.2 million foreign exchange loss versus a $1.3 million gain in the prior-year period, and higher tax expense. Adjusted EBITDA was a loss of $9.1 million compared with a $3.3 million loss in the first quarter of 2025. McCombe said the company expects adjusted EBITDA to improve in later quarters with seasonally higher revenue and reiterated an expectation of positive adjusted EBITDA for full-year 2026. Cytek ended the quarter with $262.2 million in cash, cash equivalents, and marketable securities, compared with $261.5 million at the end of 2025, which McCombe said provides flexibility to invest in growth priorities. Management reaffirmed full-year 2026 revenue guidance of $205 million to $212 million, assuming no change in currency exchange rates. McCombe said the outlook reflects recent positive growth in the U.S. and APAC and “some stabilization in the EU.” In response to a question from Stephens’ Mason Carrico about achieving the high end of the growth range, McCombe said the framework assumes continued growth in services and reagents consistent with recent quarters, “flat to modest growth in instruments,” and a contingency for macro risks. He said the company feels “very comfortable” with services and reagents and added that the first quarter showed positive instrument growth. McCombe also provided customer mix for the quarter, saying the overall mix was 62% biopharma/distributor/CRO and 38% academic and government, compared with 58%/42% for full-year 2025. Asked about Aurora Evo specifically, he said the company does not typically report mix at that level but described the product as designed for pharma customers due to “higher throughput,” while also seeing strong reception across segments. Jiang added that the system includes “integrated intelligence,” automatic shutdown and turn-on features for scheduling, and “integrated nanoparticle detection.” Piper Sandler’s David Westenberg asked about NIH funding uncertainty and its impact on U.S. academic and government demand. McCombe said U.S. academic and government performance in the quarter “was up substantially” and represented Cytek’s “strongest first quarter in U.S. academic and government” in years, potentially ever. He noted that the NIH budget is still under discussion in Congress and said the administration’s initial proposal was “not as draconian” as the prior year’s initial proposal. On sales and marketing investment, McCombe said the first-quarter decline in sales and marketing expense was “more of a quarterly blip than a trend,” adding that Cytek expects to continue investing “aggressively” for the balance of the year. Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods. The company's core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters. The article "Cytek Biosciences Q1 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for May 2026.